Hong Kong and Macau suspend BioNTech vaccines in packaging defect

Hong Kong and Macau temporarily suspended Covid vaccines manufactured by BioNTech SE due to a packaging defect, hampering cities’ efforts to revive their pandemic-affected economies.

Both governments said on Wednesday that they had received notifications about packaging defects in vials of Shanghai Fosun Pharmaceutical Group Co., which has the right to develop and market vaccines in mainland China, Hong Kong, Macau and Taiwan. BioNTech and Fosun Pharma have initiated an investigation into the matter and say there is no reason to believe that the product’s safety is at risk, according to a statement from the Macau government.

Hong Kong Suspends BioNTech Vaccines in Packaging Defect

A community vaccination center that manages BioNTech Covid-19 is temporarily closed on March 24.

Photographer: Kyle Lam / Bloomberg

The suspension marks the latest setback for the vaccine’s launch in Hong Kong, which has been slowed by public mistrust in the Beijing-backed government. While the acquisition of the BioNTech jab started to surpass the shots made by the Chinese company Sinovac Biotech Ltd., concerns about packaging defects risk undermining public confidence in both options.

.Source